STOCK TITAN

Brooks Gabriel plans Rule 144 sale of Solid Biosciences (SLDB) stock

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Solid Biosciences shareholder Brooks Gabriel filed a Rule 144 notice to sell 12,616 shares of common stock through E*TRADE on NASDAQ, with an aggregate market value of $81,267.65. The filing shows 82,569,192 shares of common stock outstanding.

The 12,616 shares were acquired the same day via settlement of vested restricted stock units as compensation from the issuer. The notice also reports that Gabriel sold 28,335 shares of common stock in a prior transaction on 02/02/2026, generating gross proceeds of $182,389.56.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the SLDB Rule 144 filing by Brooks Gabriel disclose?

The filing shows Brooks Gabriel intends to sell 12,616 shares of Solid Biosciences common stock under Rule 144. These shares were acquired via vested restricted stock units and will be sold through E*TRADE on NASDAQ, with an indicated market value of $81,267.65.

How many Solid Biosciences (SLDB) shares are being sold in this notice?

The notice covers a planned sale of 12,616 shares of Solid Biosciences common stock. The shares are to be sold through E*TRADE on NASDAQ, with the table showing an aggregate market value of $81,267.65 for this transaction.

How were the SLDB shares in this Rule 144 filing acquired?

The 12,616 Solid Biosciences shares were acquired on 02/04/2026 through settlement of vested restricted stock units. The filing describes the nature of the acquisition as compensation from the issuer, rather than a cash purchase in the open market.

What prior Solid Biosciences stock sales by Brooks Gabriel are disclosed?

The document reports that Brooks Gabriel sold 28,335 shares of Solid Biosciences common stock on 02/02/2026. Those sales generated gross proceeds of $182,389.56, and are listed as securities sold during the past three months.

How many Solid Biosciences (SLDB) shares are outstanding in this filing?

The securities information table lists 82,569,192 shares of Solid Biosciences common stock outstanding. This figure provides context for the size of the planned 12,616-share Rule 144 sale relative to the company’s total common stock base.

Which broker and exchange are used for this SLDB Rule 144 sale?

The notice identifies E*TRADE Financial Corporation as the broker for the transaction. The shares of Solid Biosciences common stock are expected to be sold on the NASDAQ exchange, with an approximate sale date listed as 02/04/2026.
Solid Bioscience

NASDAQ:SLDB

View SLDB Stock Overview

SLDB Rankings

SLDB Latest News

SLDB Latest SEC Filings

SLDB Stock Data

761.55M
65.05M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
CHARLESTOWN